Modafinil

Limits on what this shows

• Why no grade: The rotenone-toxicity study supporting the Oxidative stress entry above (Seadawy et al, 2020) measured downstream oxidative, inflammatory, and apoptotic markers, not mitochondrial structure or function directly (no membrane-potential assay, no respiratory-complex activity, no biogenesis marker reported in the material reviewed), so it is used to support that entry only and is not extended here. Modafinil's mechanism plausibly touches mitochondrial demand indirectly (a wake-promoting drug that increases neuronal activity could plausibly increase mitochondrial workload), but no source located in this review measured that directly, so per Step 7 a purely theoretical, unmeasured mechanism does not clear even the yellow bar.

Tooling disclosure

Repair pass, 2026-09-30, dedicated re-research. A fresh WebSearch attempt for this category was refused before running because this session's web-search budget was already at its 200-of-200 cap, confirming the budget is shared rather than dedicated to this task. PubMed's search-listing page (https://pubmed.ncbi.nlm.nih.gov/?term=modafinil+mitochondria) returned an HTTP 429 proxy rejection; the Europe PMC REST API, the Semantic Scholar Graph API, and the OpenAlex works-search API each also returned persistent HTTP 429 responses this session. A Crossref query, "modafinil mitochondrial biogenesis respiratory chain," succeeded once paced with an identifying mailto parameter and interleaved with other-host fetches, returning only general mitochondrial-biogenesis literature (SpringerReference, ACS Nano, Oxford Genetics of Mitochondrial Disease, and others) with zero modafinil-specific hits, consistent with the three independently phrased Crossref queries the earlier pass ran on this same category. The FDA label PDF, NCBI Bookshelf StatPearls, and drugs.com's modafinil pages were also directly re-fetched this pass and confirm no mitochondrial-function language anywhere in those sources. Given this repeated, multi-channel null result across two separate research passes, this is treated as a genuine literature gap.

Limits on what this shows

• Key null/negative findings: No modafinil-only, non-rotenone-challenged comparator arm was found in the material reviewed, so whether modafinil alters oxidative-stress markers in an undamaged system, rather than only attenuating toxin-induced injury, is untested. The doses used (0.1 to 0.3 mg/kg in mice) are far below typical human clinical mg/kg exposure at the standard 200 mg adult dose and cannot be assumed pharmacodynamically proportional.
• At-risk subgroups: None established in humans.

Regulatory status

Not addressed in the FDA label; no labeled oxidative-stress or redox monitoring parameter.

Population evidence

Seadawy, El-Shamarka, Afify, Abdel-Salam, and Abouefadle, 2020, Egyptian Journal of Chemistry, 63(12). Male albino mice given rotenone (1.5 mg/kg subcutaneous, 3 times weekly) with or without concurrent oral modafinil at 0.1, 0.2, or 0.3 mg/kg daily for 2 weeks. Versus rotenone alone, rotenone plus modafinil significantly decreased lipid peroxidation and nitric oxide, restored reduced glutathione, decreased tumor necrosis factor-alpha and interleukin-1-beta, reduced caspase-3-mediated apoptosis in the substantia nigra and striatum, and partially reversed rotenone-induced dopamine depletion, largely in a dose-dependent pattern across the three modafinil doses tested.

Mechanism

Tier B, drug-specific, in vivo, disease-model. The paper frames this as antioxidant and anti-inflammatory attenuation of rotenone's mitochondrial Complex I toxicity; the precise molecular target responsible for modafinil's antioxidant effect is not established by the material reviewed.

Counter-evidence held on record

No human oxidative-stress marker study (malondialdehyde, total antioxidant capacity, total oxidant status, superoxide dismutase, glutathione) in modafinil-treated patients was located despite searches across multiple phrasings; this entry rests entirely on one animal disease-model paper, and no modafinil-alone (non-toxin-challenged) arm was found within it. Do not use this finding to justify antioxidant supplementation or to claim modafinil is broadly "protective." The model specifically challenges mitochondrial Complex I with a neurotoxin at doses far below typical human clinical exposure, a condition unrepresentative of ordinary clinical use, and no dose recommendation follows from a cell-protective or animal-protective finding.

Limits on what this shows

• Why no grade: Copper is the cofactor for dopamine-beta-hydroxylase, an enzyme in the same catecholamine pathway that modafinil's dopamine-transporter-inhibiting action sits near, the same two-step mechanistic adjacency this series' atomoxetine dossier disclosed and explicitly did not treat as sufficient for a grade. Modafinil's own documented mechanism is presynaptic dopamine-reuptake inhibition, not de novo catecholamine synthesis or vesicular release, so this adjacency describes a pathway modafinil sits near, not a demonstrated effect on copper status, and no source located in this review tested the latter at any tier, drug-specific or class-level.

Tooling disclosure

Repair pass, 2026-09-30, dedicated re-research. WebSearch was refused outright (session budget already at 200 of 200). PubMed's search-listing page for "modafinil copper" returned a reCAPTCHA verification page rather than results, and a retry a short time later was proxy-rejected with HTTP 429 and an explicit instruction not to retry that host again this session; the Europe PMC, Semantic Scholar, and OpenAlex APIs were also persistently 429. A Crossref query, "modafinil copper ceruloplasmin," succeeded once paced with a mailto parameter, surfacing only general ceruloplasmin and copper-metabolism literature (biologic variation of serum copper/ceruloplasmin, copper transport biochemistry, dairy-cattle and Alzheimer's copper studies) with zero modafinil-specific hits, and the previously planned dopamine-beta-hydroxylase-paired query was again unreachable this pass. drugs.com's food-interaction and drug-interaction index pages for modafinil were directly re-fetched and name no copper or trace-element interaction of any kind. Given the consistent null result across two independent research passes and multiple channels, this is treated as a genuine gap.

Limits on what this shows

• Why no grade: One mechanistically adjacent but insufficient source was found: Ueki, Rosen, Andbjer, et al, 1993, Experimental Brain Research, reported that modafinil counteracted the reduction of tyrosine-hydroxylase immunoreactivity and dopamine stores in nigrostriatal dopamine neurons after partial dopaminergic-pathway transection in rats. Tyrosine hydroxylase is an iron-dependent enzyme, but this study measured TH protein immunoreactivity and tissue dopamine content, not iron status or an iron-dependent functional parameter, and the direction reported is protective and restorative under a lesion-injury model, not a depletion signal. It is disclosed here but is insufficient to support even a yellow grade because no iron parameter was actually measured. The amphetamine and methylphenidate-family literature in this series includes discontinuation and add-on iron-supplementation trials, but every one of those trials enrolled patients on a stimulant with vesicular dopamine-releasing action, a pharmacologically distinct mechanism from modafinil's reuptake-inhibition-only profile, so per Hard Rule 6 that class literature is not carried forward here.

Tooling disclosure

Repair pass, 2026-09-30, dedicated re-research. WebSearch was refused outright (session budget already at 200 of 200). This category is the one where PubMed's own search interface was actually reached this pass: https://pubmed.ncbi.nlm.nih.gov/?term=modafinil+AND+iron+AND+ferritin returned cleanly with an explicit zero-result count, a direct confirmation from PubMed's own indexing, not only Crossref's, that no modafinil-and-iron-and-ferritin literature is indexed there. The Europe PMC, Semantic Scholar, and OpenAlex APIs were persistently 429 this pass and a subsequent Crossref retry for a further iron phrasing ("modafinil serum iron transferrin") was itself proxy-rejected with HTTP 429 and an instruction not to retry that endpoint again this session, so it was not repeated. drugs.com's drug-interaction index for modafinil was also directly re-checked and lists no iron or mineral-supplement interaction. Combined with the earlier pass's two clean Crossref queries and the disclosed-but-insufficient Ueki et al 1993 tyrosine-hydroxylase source, this is treated as a genuine gap, now corroborated by a direct PubMed zero-result search in addition to Crossref.

Limits on what this shows

• Why no grade: Two independently phrased Crossref searches, "modafinil gut microbiota" and "modafinil intestinal permeability gut brain axis," both returned zero modafinil-specific hits, surfacing only unrelated general gut-brain-axis, dysbiosis, and intestinal-barrier literature with no modafinil-dosed cohort in any result. No modafinil-specific or wakefulness-agent class-level microbiome study was located.

Tooling disclosure

Repair pass, 2026-09-30, dedicated re-research. WebSearch was refused outright (session budget already at 200 of 200). PubMed's search-listing page for "modafinil gut microbiome" returned a reCAPTCHA verification page rather than results, and the Europe PMC, Semantic Scholar, and OpenAlex APIs were persistently 429. A Crossref query, "modafinil gut microbiota intestinal," succeeded once paced with a mailto parameter, surfacing only general gut-dysbiosis, P-glycoprotein/microbiota, and antibiotic-dysbiosis literature with zero modafinil-specific hits, consistent with the earlier pass's two independently phrased, cleanly-returned Crossref queries on this category. drugs.com's food-interaction page for modafinil was also directly re-checked and names no probiotic, gut, or microbiome-related interaction. Given the consistent null result across two independent research passes and multiple channels, this is treated as a genuine gap.

Limits on what this shows

• Key null/negative findings: No dose-response arm, no chronic-dosing arm, and no oral-route arm were located in this source; the 600 mg/kg intraperitoneal rat dose is far above typical human oral exposure (200 mg/day in an adult, roughly 2.9 mg/kg at 70 kg) on a straight mg/kg basis and cannot be assumed pharmacodynamically proportional to therapeutic human dosing. No direct ATP concentration, oxygen-consumption-rate, or mitochondrial-respiration measurement was located for modafinil at any tier in this repair pass.
• At-risk subgroups: None established in humans; this is an acute rodent finding only.

Regulatory status

Not addressed in the FDA label; no labeled ATP, phosphocreatine, or cellular-energy monitoring parameter.

Population evidence

Pierard, Satabin, Lagarde, Barrere, Guezennec, Menu, and Peres, 1995, Brain Research 693(1-2):251-256. Anesthetized male rats given a single intraperitoneal dose of modafinil (600 mg/kg) were examined by in situ 2D COSY 1H-NMR spectroscopy of brain tissue. Versus control values, modafinil significantly increased aspartate (72% plus or minus 15%), the glutamate-glutamine pool (28% plus or minus 8%), inositol (51% plus or minus 19%), and the creatine-phosphocreatine pool (47% plus or minus 14%) (P less than 0.05, n=5 per group). The authors concluded the awakening properties of modafinil could be mediated by this metabolic activation.

Mechanism

Tier B, drug-specific, in vivo, acute dosing, non-disease model. Creatine-phosphocreatine is the brain's rapid ATP-buffering system via the creatine kinase reaction, so a significant increase in this pool is read here as a signal of increased energy-metabolite turnover or availability accompanying modafinil-induced arousal, not as a direct measurement of ATP synthesis rate, mitochondrial respiration, or ATP concentration itself, which this study did not assay.

Counter-evidence held on record

No modafinil-specific human ATP, phosphocreatine, or mitochondrial-respiration study was located despite a dedicated repair-pass search across PubMed, Europe PMC, Semantic Scholar, OpenAlex, and Crossref; this entry rests entirely on one acute, supraphysiologic-dose animal study, and no oral or chronic-dosing arm exists within it. Do not use this finding to justify an energy, creatine, or ATP-support supplement, or to claim modafinil broadly boosts cellular energy production in humans at therapeutic doses. The dose studied (600 mg/kg intraperitoneal in rats) is far above ordinary human oral exposure, the model is acute and anesthetized, and no dose recommendation follows from an animal metabolic-activation signal.

Limits on what this shows

• Why no grade: The FDA label's clinical-trial section states that "clinical chemistry, hematology, and urinalysis parameters were monitored," but reports no anemia, hemoglobin, or hematocrit signal anywhere in the document reviewed. The only hematologic language in the label concerns rare multi-organ hypersensitivity reactions, which can include eosinophilia, leukopenia, and thrombocytopenia, immune-cell and inflammatory findings unrelated to red-cell mass or oxygen-carrying capacity. A Crossref search combining modafinil with hemoglobin, hematocrit, erythropoiesis, and red-blood-cell terms returned zero modafinil-specific hits, surfacing only unrelated sickle-cell and general erythropoiesis literature.

Tooling disclosure

Repair pass, 2026-09-30, dedicated re-research. WebSearch was refused outright (session budget already at 200 of 200). PubMed's search-listing page and the Europe PMC, Semantic Scholar, and OpenAlex APIs were each persistently 429 this pass. A Crossref query, "modafinil hemoglobin erythropoiesis red blood cell," succeeded once paced with a mailto parameter, surfacing a single unrelated result (a fetal-hemoglobin/sickle-cell-disease dissertation studying hydroxycarbamide, not modafinil), consistent with the earlier pass's clean Crossref result on this category. The full FDA label PDF was also directly re-fetched and re-searched this pass for anemia, hemoglobin, hematocrit, red blood cell, and erythropoiesis language; the only hematologic entry found anywhere in the label remains the postmarketing "Hematologic: agranulocytosis" line, an immune-cell finding unrelated to oxygen-carrying capacity. rxlist.com and MedlinePlus's modafinil pages were also directly checked and contain no hemoglobin, hematocrit, or oxygen-delivery language. Given this repeated, multi-channel null result across two research passes, this is treated as a genuine gap.